Results 111 to 120 of about 109,024 (308)

Estimates of influenza vaccine effectiveness in primary care in Scotland vary with clinical or laboratory endpoint and method : experience across the 2010/11 season [PDF]

, 2013
Aim: This study examines estimation of seasonal influenza vaccine effectiveness (VE) for a cohort of patients attending general practice in Scotland in 2010/11.
Kavanagh, Kimberley, McMenamin, Jim, Robertson, Charles   +2 more
core   +3 more sources

Developing Biomaterial‐Based mRNA Delivery System for Lung Disease Treatment

Advanced Science, EarlyView.
Schematic illustration of biomaterial delivery mRNA for the treatment of lung diseases. Abstract Lung disease remains a persistent global health challenge. Advances in medical research have led to innovative strategies to combat these conditions, with biomaterials emerging as a promising platform for targeted drug delivery.
Qiancheng Gu, Huaqian Xue, Zhiyun Liu, Jiameng Rao, Lingyao Zeng, Chen Zhang, Lanjie Lei, Liyun Shi   +7 more
wiley   +1 more source

Vaccination Hesitation: Investigation Why Parents Decline Pediatric Influenza Vaccines in Juneau, Alaska [PDF]

, 2015
The influenza virus is responsible for hundreds of childhood deaths and costs the health care system millions of dollars each year (Hassan, Lewis, Davis, Gebremariam, and Dombkowski, 2009).
Leder, Lindsey
core  

ADAR1 as a Placental Innate Immune Rheostat Sustaining the Homeostatic Balance of Intrinsic Interferon Response at the Maternal‐Fetal Interface

Advanced Science, EarlyView.
This study reveals that ADAR1, an RNA‐editing enzyme, fine‐tunes immune responses in the placenta by preventing the accumulation of immunogenic double‐stranded RNAs (dsRNAs) from interferon‐stimulated genes. The loss of ADAR1 in the placenta leads to excessive interferon signaling restricted to the junctional zone, disrupting placental development and ...
Xiaogang Chen, Xiangchao Xu, Jiahao Chen, Huiru Zhang, Wanshan Zheng, Wenzhe Yu, Xiaoqian Hu, Bin Cao   +7 more
wiley   +1 more source

M2e-Based Universal Influenza A Vaccines

Vaccines, 2015
The successful isolation of a human influenza virus in 1933 was soon followed by the first attempts to develop an influenza vaccine. Nowadays, vaccination is still the most effective method to prevent human influenza disease.
Lei Deng, Ki Joon Cho, Walter Fiers, Xavier Saelens   +3 more
doaj   +1 more source

Influenza vaccines and immunopathology [PDF]

Expert Review of Vaccines, 2012
“…the concern over immunopathology resulting from T-cell responses to nucleoprotein or other conserved antigens in the absence of neutralizing antibodies in humans can be narrowed to high-dose infections with some pandemic viruses, although both in 1918 and 2009, there is evidence that T-cell responses were more likely to be responsible for protection ...
openaire   +3 more sources

EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy

Advanced Science, EarlyView.
This review provides new perspectives on EGFR's activation, mutations, and their impact on tumor immunotherapy. It summarizes how EGFR is activated and the current EGFR targeting strategy, evaluates their clinical outcomes in combination with immunotherapy, highlighting differential responses in tumors with EGFR wild‐type and different mutants.
Yuanzhuo Gu, Hongchao He, Shilei Qiao, Yifan Shao, Lurong Wang, Zhengkui Zhang, Long Zhang, Fangfang Zhou   +7 more
wiley   +1 more source

Research Progress of Universal Influenza Vaccine

Vaccines
Influenza viruses continue to undergo antigenic drift and shift, resulting in the need to update existing vaccines annually. Therefore, the development of a universal influenza vaccine has become an urgent global need. This paper reviews the functions of
Liangliang Wang, Qian Xie, Pengju Yu, Jie Zhang, Chenchen He, Weijin Huang, Youchun Wang, Chenyan Zhao   +7 more
doaj   +1 more source

Developing a Personalized Cancer Nanovaccine Using Coxsackievirus‐Reprogrammed Cancer Cell Membranes for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
A personalized nanovaccine combining PLGA‐encapsulated heat‐inactivated CVB3 and membranes from CVB3‐infected breast cancer cells stimulates potent antitumor immunity. It reduces immunosuppressive markers, enhances immune activation, and improves survival in vivo.
Amirhossein Bahreyni, Yasir Mohamud, Amrit Singh, Razieh Sadat Banijamali, Jeffrey Tang, Jingchun Zhang, Honglin Luo   +6 more
wiley   +1 more source

Vaccination nation? Civilised strategies for protecting outdoor poultry from Avian Flu H5N1 [PDF]

, 2006
An analysis of the threat of H5N1 Avian Flu virus to the UK, the potential impact on UK organic and free range poultry production and the evidence for a policy of ...
Sanders, Richard
core